Validates the use of the RAPID score for predicting mortality in pleural infections, directly informing the management of patients undergoing pleural interventions like chest tubes and medical thoracoscopy.
Abstract
Interstitial lung diseases (ILDs) require early recognition and longitudinal assessment, yet repeated high-resolution computed tomography (HRCT) is often limited by access, cost, and cumulative radiation exposure, particularly in connective tissue disease-associated ILD (CTD-ILD). Lung ultrasound (LUS) is a bedside, radiation-free, repeatable adjunct that primarily evaluates B-line burden and pleural-line abnormalities. In this review, we summarize core sonographic signs and key diagnostic pitfalls, and synthesize the evidence for three clinical domains: screening, case finding and triage in high-risk populations, phenotype-relevant cues, and interval monitoring between HRCT examinations, ideally alongside pulmonary function tests. We further compare scanning protocols and scoring approaches, including B-line-dominant, pleural-line-dominant, and composite frameworks, and outline practical strategies for harmonized acquisition, reproducible scoring, and structured reporting. We also review the emerging role of artificial intelligence in acquisition guidance, quality control, and feature quantification, while emphasizing important boundaries related to device variability, disease-spectrum shift, and limited specificity. Current evidence most strongly supports LUS as a complementary tool for screening, triage and bedside trend monitoring, particularly in CTD-ILD, whereas phenotype-oriented interpretation, progression-sensitive markers, and AI-enabled deployment remain developmental. Future priorities include multicentre harmonization of protocols and scoring, prospective validation of clinically meaningful change, and transparent external evaluation to support safe integration into multidisciplinary care pathways.
Keep reading
N opens the next oneUltrasound estimation of pleural fluid volume is a core procedural skill for thoracentesis and chest tube placement, making this directly relevant to IP practice.
Directly impacts pleural management and staging by maximizing the diagnostic yield of routine thoracentesis for molecular testing in malignancy.
Pleural fluid obtained during thoracentesis or medical thoracoscopy should be preserved for cfDNA molecular testing when tissue is limited.
Relevant to pleural disease management and post-procedural care of trapped or non-expandable lungs.
Provides useful risk stratification tools for managing secondary spontaneous pneumothorax patients who often require IP intervention.